The few currently available pharmacological treatments for opioid addiction fall into one of two categories: substitution therapies or abstinent therapies. Substitution therapies (i.e., methadone, buprenorphine, and buprenorphine / naloxone combination) prevent a patient from experiencing withdrawal symptoms but allow the patient to still experience a limited “high” without taking any illicit opioids. Abstinent therapies (i.e., naltrexone) block the euphoric effect of opioids if a patient attempts to take an illicit opioid. However, all of these drugs are associated with clinical shortcomings in efficacy, safety, and/or delivery, creating opportunities for new and improved alternatives. This report examines physicians’ key treatment drivers and analyzes the greatest areas of unmet treatment need and thereby the opportunities in this space.
Questions Answered
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European psychiatrists fielded in November 2018
Key companies: Indivior, Orexo, Braeburn Pharmaceuticals, Camurus
Key drugs: Suboxone Film, Subutex, Sublocade, Zubsolv, methadone, naltrexone
Key metrics included:
Product Description
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.